The U.S. Food and Drug Administration granted platform technology designation to Precigen Inc.'s AdenoVerse immunotherapeutic platform. The designation applies to therapies targeting HPV‑positive malignancies, including head and neck, cervical, anal, vulvar and vaginal cancers.
AdenoVerse gained the status after its use in PAPZIMEOS, a treatment approved in August 2025 for adults with recurrent respiratory papillomatosis. The platform designation allows Precigen to leverage data, manufacturing knowledge and pre‑clinical information from PAPZIMEOS to support future marketing applications, and enables earlier engagement with the FDA and consideration of prior manufacturing inspections.
Precigen, a commercial‑stage biopharmaceutical company based in Germantown, Maryland, said the designation will help it advance additional AdenoVerse‑based therapies. President and CEO Helen Sabzevari noted that the status permits the company to use existing data and interact with regulators more frequently for upcoming products.
The AdenoVerse pipeline includes two Phase 2 studies of PRGN‑2009 combined with pembrolizumab: one in newly diagnosed HPV‑associated oropharyngeal squamous cell carcinoma and another in recurrent or metastatic cervical cancer. An open‑label study is also enrolling patients for a redosing evaluation of PAPZIMEOS in recurrent respiratory papillomatosis.
The FDA’s platform technology designation requires that a platform be used in an approved product, be well characterized, reproducible and adaptable across multiple products without compromising quality, manufacturing or safety. Precigen now aims to apply the AdenoVerse platform to additional immuno‑oncology, autoimmune and infectious‑disease indications.
